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Brief Communications
Integrin Activation Promotes Axon Growth on Inhibitory
Chondroitin Sulfate Proteoglycans by Enhancing Integrin
Signaling
Chin Lik Tan,1 Jessica C. F. Kwok,1 Rickie Patani,1,2 Charles ffrench-Constant,3 Siddharthan Chandran,1,2,4
and JamesW. Fawcett1
1Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0PY, United Kingdom, 2The Anne McLaren
Laboratory for Stem Cell Biology and Regenerative Medicine, Cambridge CB2 0SZ, United Kingdom, 3Centre for Multiple Sclerosis Research, MRC Centre
for Regenerative Medicine, University of Edinburgh, Queens’ Medical Research Institute, Edinburgh EH16 4TJ, United Kingdom, and 4Centre for Clinical
Brain Sciences, MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4SB, United Kingdom
Chondroitin sulfate proteoglycans (CSPGs) are upregulated after CNS lesions, where they inhibit axon regeneration. In order for axon
growth and regeneration to occur, surface integrin receptors must interact with surrounding extracellular matrix molecules. We have
explored the hypothesis that CSPGs inhibit regeneration by inactivating integrins and that forcing integrins into an active state might
overcome this inhibition. Using cultured rat sensory neurons, we show that the CSPG aggrecan inhibits laminin-mediated axon growth by
impairing integrin signaling via decreasing phosphorylated FAK (pFAK) and pSrc levels, without affecting surface integrin levels. Forcing
integrin activation and signaling bymanganese or an activating antibodyTS2/16 reversed the inhibitory effect of aggrecan onmixed aggrecan/
laminin surfaces, and enhanced axon growth from cultured rat sensory neurons (manganese) and human embryonic stem cell-derived mo-
toneurons (TS2/16). The inhibitory effect of Nogo-A can also be reversed by integrin activation. These results suggest that inhibition by CSPGs
can act via inactivation of integrins, and that activation of integrins is a potentialmethod for improving axon regeneration after injury.
Introduction
Chondroitin sulfate proteoglycans (CSPGs) are upregulated at
sites of damage in theCNS, inhibiting axon regeneration (Tang et
al., 2003; Silver and Miller, 2004). Of the several inhibitory
CSPGs that are present, aggrecan has been shown to be strongly
inhibitory to neurite outgrowth from several types of cultured
neurons (Borisoff et al., 2003; Chan et al., 2008). It may act via
several mechanisms, including the transmembrane protein ty-
rosine phosphatase  (PTP) receptor (Shen et al., 2009) or the
epidermal growth factor receptor (EGFR) (Koprivica et al.,
2005), and through a variety of downstream signaling cascades,
such as Rho/ROCK pathway or protein kinase C (PKC) (Mon-
nier et al., 2003; Sivasankaran et al., 2004). Aggrecan is synthe-
sized primarily by neurons and is endogenously present in the
CNS (Asher et al., 1995; Li et al., 1996). It is also modulated after
a CNS injury at the lesion site, where it is secreted by reactive
astrocytes (Silver and Miller, 2004; Afshari et al., 2010).
Growth cone migration and axon extension require an adhe-
sion molecule as a physical link between the cell and its substrate
(Long and Lemmon, 2000; Previtali et al., 2001; Song and Poo,
2001). For interaction withmolecules present in the extracellular
matrix (ECM), the main receptors are integrins, which function
as both adhesion and signaling molecules (Hynes, 2002; Lemons
and Condic, 2008). Integrins are  heterodimeric transmem-
brane receptors, whose functions are regulated by two different
but related processes, “inside-out” and “outside-in” signaling.
The former (also termed “integrin activation”) indicates a change
from a low ligand-binding affinity (inactive) conformation to a
high-affinity (active) one. “Outside-in” signaling refers to the
signaling cascades propagated intracellularly upon ligand–integ-
rin binding. In the nervous system, integrins are involved in axon
guidance, neurite extension, synaptic plasticity, and axon regen-
eration [for review, see Reichardt et al. (1989) and Lemons and
Condic (2008)]. Previous work has indicated that the CNS inhib-
itorymolecule Nogo-A exerts some of its effects through integrin
inactivation (Hu and Strittmatter, 2008). Here we have investi-
gated whether the effect of aggrecan in impairing axon regeneration
could also be mediated though an integrin-related mechanism,
and whether manipulation of integrins can allow axons to over-
come this inhibition.
Materials andMethods
Dorsal root ganglion neuron culture. Dorsal root ganglia (DRGs) were
dissected from adult male Sprague Dawley rats (3 months). The neu-
rons were dissociated with collagenase and 0.1% trypsin, centrifuged
through a 15% bovine serum albumin (BSA) density gradient, and cul-
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tured in DRG culture medium [DMEM,
insulin-transferrin-selenium (1), penicillin-
streptomycin-fungizone (1), and NGF (10
ng/ml)]. Cultures were kept for 20 h at 37°C in
7% CO2. Where relevant, 500 M manganese
was added only after neurons were attached to
coverslips (2 h after plating). For removing
the glycosaminoglycan (GAG) chains on ag-
grecan, chondroitinase ABC (Sigma, C2905,
0.1U/ml)was added to aggrecan for 1 h at 37°C
before using it for coating/treatment on DRG
cultures.
Human embryonic stem cell-differentiated
motoneuron culture. Human embryonic stem
cell (hESC) lines (H9 from theWiCell Research
Institute and HuES9 from hES facility, Har-
vard University) between passages 50 and 90
were used for this study. hESC culture andneu-
ral induction were performed using a protocol
adapted from Patani et al. (2009). Briefly,
hESCs were propagated in defined medium
supplemented with 8 ng/ml FGF2, 10 ng/ml
Activin (Harrington et al., 2006), and 10 ng/ml
insulin. To generate neural precursor cells
(NPCs), hESCs were enzymatically and me-
chanically dissociated before being plated in
chemically definedmedium, comprising 50% Is-
cove’s modified Dulbecco’s medium (IMDM),
50% F12 and GlutaMAX, supplemented with
1.75 mM human recombinant insulin, 0.38 mM
transferrin, 450 M monothioglycerol, 10 l/ml
lipids, and 5mg/ml BSA fraction V on an orbital
shaker. For spinal motoneuron specification,
hESC-NPCswere cultured in 10–20 ng/ml FGF2
and 0.5 M RA/1 M purmorphamine. For ter-
minal differentiation, hESC-NPCswere cultured
on laminin-coated coverslips in DMEM supple-
mented with B27, PSF, 10 ng/ml BDNF, and 10
ng/ml GDNF.
For experiments involving the TS2/16 anti-
body (ATCC-HB243, Hybridoma Bank), hESC-
NPCs were plated on coverslips coated with
laminin or aggrecan–laminin and cultured in the
differentiation medium (as described above) for
2 d at 37°C. Then, TS2/16 was added at 1:3 dilu-
tion, and the cultures were kept for another day.
Postfixation immunostaining. Cell cultures
on coverslips were fixed with 4% paraformal-
dehyde (PFA), permeabilizedwith 0.1%Triton
X-100, blocked with goat serum, and incubated with primary antibodies
at 4°C overnight. Then, coverslips were incubated with secondary anti-
bodies for 1 h before mounting on slides. Primary antibodies were used
against pY397 FAK (Biosource, 44-624G, 1:100), pY861 FAK (Abcam,
ab4804, 1:100), pY418 Src (Invitrogen, 44-660G, 1:100), FAK (Biosource,
AHO0502, 1:100), III tubulin (Sigma, T8660, 1:400), neurofilament-H
(Biomol, NA1211, 1:1000), laminin (Sigma, L9393, 1:100), and CS-56
(Sigma, C8035, 1:500).
Live immunostaining. 9EG7 antibody (BD Pharmingen, 550531, 1:50
in culture medium) was added to the cultures for 15 min at 37°C. After
washing once with culturemedium, the cultures were fixed with 4%PFA
and incubated with FITC-conjugated goat anti-rat antibody for 1 h be-
fore mounting on slides.
Western blotting. Cell lysates from manganese- or aggrecan-treated
DRG cultures were lysed and collected in RIPA buffer (Roche), supple-
mented with protease inhibitor and phosphatase inhibitor cocktails
(Roche). The protein concentrations were then determined using BCA
Protein Assay Kit (Pierce). Protein extracts were subjected to SDS-PAGE
and blotted onto polyvinylidene difluoride (Hybond-P)membranes (GE
Healthcare).Membranes were blockedwith 5% skimmedmilk in TBS-T,
before incubation with rabbit anti-pY397 FAK (Biosource) or mouse
anti-FAK (Millipore) antibodies at 4°C overnight. This was followed by
incubation in HRP-conjugated anti-rabbit or anti-mouse antibodies at
room temperature for 1 h. Protein bands were visualized using ECL-
detecting reagents (GE Healthcare).
Axon growth assay. For adult DRG neurons, two parameters were
quantified: (1) percentage of neurons with axons longer than the cell
body diameter; (2) average of the longest axons extended by each neuron.
For hESC-derivedmotoneurons, the lengths ofIII tubulin-positive (for
differentiated neurons) axons extended bymotoneuronsweremeasured.
Quantitative immunofluorescence. At least 20 axons per coverslip were
first selected at random and imaged. An area of axon (30m long) was
then traced, and the fluorescence intensity of immunostaining was ana-
lyzed using the Leica Application Suite (Leica Microsystems).
Results
Axon growth is inhibited by aggrecan
We cultured adult rat DRG neurons on the integrin substrate
laminin, which is relevant because it is present in large amounts
around Schwann cells and bands of Bungner, which support axon
Figure 1. Axon growth from DRG neurons on laminin and aggrecan–laminin substrata. A, DRG axon growth on varying con-
centrations of laminin (n 6). B, Axon growth is inhibited by the presence of aggrecan (n 3). C, Mixed aggrecan–laminin
coating does not affect the final levels of laminin coated on coverslips. Aggrecan level was quantified based on CS-56 immuno-
staining. D, ChABC treatment removes the axon growth inhibition induced by aggrecan. E, ChABC treatment reduces the amount
of chondroitin sulfate coatedas substratum. Scale bar, 100m.Data aremean SEM, analyzedwith Student’s t test. **p0.01;
*p 0.05.
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regeneration after peripheral nerve injury. Axon growth after
20 h was assessed by measuring the percentage of neurons with
axons, and the longest axon extended by each neuron. Axons
grew profusely on laminin, the length of axons and the propor-
tion of regenerating neurons varying with the concentration of
laminin used for coating (Fig. 1A). Addition of aggrecan to the
substrate inhibited axon growth at all laminin concentrations,
although the effect gradually diminished with increasing laminin
concentration (Fig. 1B). The addition of aggrecan to the sub-
strate did not affect the level of laminin on the growth surfaces
(p 0.84, t test, n 4) (Fig. 1C). That aggrecan inhibits growth
even at saturating levels of laminin indicates that aggrecan is not
acting simply by masking integrin binding sites on laminin. Re-
moval of glycan chains from aggrecan by treatment with chon-
droitinase ABC (ChABC) 1 h before coating eliminated its axon
growth-inhibitory effect (p  0.01, t test,
n  3) (Fig. 1D). This showed that the
main inhibitory action of aggrecan is
mediated through the glycan chains.
The reduction in the glycan level in the
substratum after ChABC treatment was
clearly observed by immunostaining of
CS-56 (Fig. 1E).
Aggrecan impairs integrin signaling
We asked whether aggrecan-induced
growth inhibition could be mediated
via an effect on integrins. DRG neurons
were cultured on laminin and allowed
to extend axons for 20 h. The neurons
were then treated with either aggrecan-
containingmedium (25g/ml) or control
medium for 2 min. Western blotting was
performed on proteins extracted from the
neurons to determine the level of intracel-
lular integrin signaling, on the basis of
the level of phosphorylated-tyrosine-397
FAK (pY397 FAK) compared to total
FAK. Aggrecan-treated neurons had a
lower level of pY397 FAK, as compared to
the control, with no difference in the level
of total FAK (Fig. 2A). Since integrin-
related events that mediate axon out-
growth primarily take place near the ends
of the axons, we performed a quantitative
immunofluorescence assay to assess the
changes of pY397 FAK in this region. As
with the whole-cell Western blot, in the
growth cone region, pY397 FAK level de-
creased by 32.3% (p 0.001, t test, n 6)
upon aggrecan treatment, without any
changes in the total FAK level (p 0.68, t
test, n  3) (Fig. 2B). Treating aggrecan
with ChABC before addition to the cul-
tures significantly removed its inhibition
on pY397 FAK level (p 0.05, t test, n
3) (Fig. 2C), suggesting that aggrecan
impairs integrin signaling via its glycan
chains.
To see whether the inhibition of integ-
rin signaling was due to a change in the
surface level of integrin, we examined the
amount of integrin on the axonal surface
after aggrecan treatment using quantitative immunohistochem-
istry on nonpermeabilized axons. Because DRG axon binding to
laminin is mediated by 1 integrins, the level of surface 1 integ-
rinwas assessed.No difference in the surface1 integrin level was
observed between aggrecan- and control medium-treated axons
(p  0.36, t test, n  3) (Fig. 2D), suggesting that aggrecan
inhibits integrin signaling without altering surface integrin
expression.
Investigating the changes in pY397 FAK over a longer time
period, we observed that pY397 FAK level was maximally de-
creased at 2 min, was less decreased at 5 min, and returned to
control level within 15min (n 3) (Fig. 2E). Since the inhibitory
effect of aggrecan on axon outgrowth is sustained and lasts much
longer than 15 min, we asked whether integrin downstream sig-
naling may exhibit a longer-lasting change. Downstream of
Figure2. Effect of aggrecanon integrin signaling.A, AggrecandecreasespY397FAK level inDRGneurons,without altering total
FAK level. B, The same effect is observed in axons and growth cones, as analyzed by quantitative immunofluorescence. Scale bar,
20m. C, ChABC treatment of aggrecan eliminates its inhibitory effect on pY397 FAK. D, Aggrecan does not alter the level of1
integrin expressed on the surface of DRG axons. Scale bar, 15m. E, The phosphorylation status of Y397 FAK, Y861 FAK, and Y418
Src residues undergoes sequential decreases after aggrecan treatment. pY397 FAK ismaximally decreased at 2min and pY861 at 5
min, while pY418 Src remains depressed for at least 15 min. Data are mean SEM, analyzed with Student’s t test. **p 0.01;
*p 0.05.
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tyrosine-397 residue phosphorylation,
“outside-in” integrin signaling is propa-
gated by the phosphorylation of other ty-
rosine residues on FAK, followed by the
activation of other signaling molecules,
such as Src. (Parsons, 2003; Mitra and
Schlaepfer, 2006). We therefore exam-
ined the phosphorylation of tyrosine-
861 FAK (pY861 FAK) and tyrosine-418
Src (pY418 Src) after aggrecan treatment
on DRG neurons. We found that the
pY861 FAK level begins to decline 5 min
after addition of aggrecan and returns to
control level within 15 min (n 3), while
pY418 Src, which is further downstream,
decreases after 5 min, and stays at this de-
pressed level for at least 15 min (n  3)
(Fig. 2E). These results are consistent with
our hypothesis that aggrecan impairs
integrin signaling. Moreover, they cor-
roborate the sequential phosphorylation
events known to occur during integrin
signaling.
Integrin activation increases axon
growth by enhancing integrin signaling
To examine the effect of integrin activa-
tion on axon growth, we cultured DRG
neurons on different laminin concentra-
tions (0.1–10 g/ml), in the presence or
absence of manganese (500 M), and as-
sessed the axon growth after 20 h.Manga-
nese is a potent integrin activator that
holds integrin receptors in a conforma-
tion with a high ligand-binding affinity
(Mould et al., 1995). At very low (0.1 g/
ml) or high (10 g/ml) laminin concen-
trations, addition of manganese did not
alter the extent of axon growth. However,
at low (1 g/ml) laminin concentration,
manganese treatment induced an increase
in axon growth (percentage of neurons
with axons, 22.0% to 30.2%, p  0.01;
axon length, 144.8 m to 184.5 m, p 
0.001, t test, n 6) (Fig. 3A,B). To verify
that there is an integrin-activating effect
of manganese, DRG cultures were immu-
nostained live using a monoclonal anti-
body, 9EG7, which recognizes activated
integrins (Bazzoni et al., 1995; Montanez
et al., 2008). Neurons cultured in manganese-containing
medium exhibited a higher level of 9EG7 immunostaining
(54.2%; p  0.01, t test, n  3) on the axons compared to
control (Fig. 3C), indicating more “active” integrins on the
surface.
The growth-enhancing effect of manganese is probably medi-
ated via increased “outside-in” integrin signaling. Therefore, the
status of pY397 FAK in DRG neuron cultures after manganese
treatment was assessed. FromWestern blot of whole-cell protein
lysate, as well as quantitative immunofluorescence of axon/
growth cone regions, pY397 FAK level was markedly enhanced
(quantitative immunofluorescence,56.1%; p 0.05, t test, n
3) in the presence ofmanganese (Fig. 3D,E), while total FAK level
remained unchanged (p  0.80, t test, n  3). Furthermore, a
time course study revealed that the pY397 FAK level began to
increase after 2 min and reached a statistically significant level
after 5 min (p 0.05, t test, n 3), before settling at a plateau of
150% of control level after 15 min (Fig. 3F).
Integrin activation overcomes aggrecan-mediated growth
inhibition by enhancing integrin signaling
Since aggrecan inactivates integrins and decreases integrin signal-
ing, we asked whether forced activation of integrins might over-
come its inhibitory effect. DRG neurons were cultured for 20 h as
before, then treated with aggrecan or mixed aggrecan–manga-
nese solutions to assess the immediate effect on integrin signal-
Figure 3. Effect of manganese-induced integrin activation on DRG neurons. A, B, Manganese-induced integrin activation
enhances axon growth from cultured DRG neurons at low (1g/ml), but not very low (0.1g/ml) or high (10g/ml), concen-
trations of laminin. Scale bar, 50 m. C, DRG axons in manganese-containing medium exhibit higher 9EG7 immunostaining
intensity. Scale bar, 15m.D, E, Manganese induces an increase in pY397 FAK level, both in whole-cell lysate (Western blot) and
axons/growth cones (quantitative immunofluorescence), without changing total FAK level. Scale bar, 20 m. F, Manganese
induces a rapid rise in pY397 FAK level, which reaches a statistically significant level within 5min and plateaus thereafter. Data are
mean SEM, and analyzed with Student’s t test. ***p 0.001; **p 0.01; *p 0.05; n.s., not significant.
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ing. Quantitative immunofluorescence analysis showed that the
decrease in pY397 FAK level brought about by aggrecan was alle-
viated by manganese treatment (p 0.01, t test, n 5) (Fig. 4A).
The ability of integrin activation to rescue axon growth on
inhibitory aggrecan was also assessed. To further dissect the po-
tential differential effects at varying substrate concentrations, two
laminin concentrations were selected to reflect “low” (1 g/ml)
or “high” (10 g/ml) ligand availability. At both concentrations,
aggrecan inhibited axon growth from DRG neurons, with the
effect being stronger at the low laminin concentration. Addition
of manganese restored the growth to control levels on both sur-
faces (percentage of neurons with axons: low laminin, 9.0% to
17.3%, p 0.01; high laminin, 27.7% to 35.5%, p 0.001; axon
length: low laminin, 85.6 m to 146.9 m, p  0.01; high
laminin, 167.4 m to 212.0 m, p  0.01, t test, n  6) (Fig.
4B,C), suggesting that integrin activation enables neurons
to overcome aggrecan-mediated inhibition to enhance axon
growth.
The effects of manganese are not entirely specific to integrin
activation. To confirm the growth-enhancing effect of manga-
nese is attributable to integrin activation, we repeated our assays
using a specific integrin activator, the monoclonal antibody
TS2/16 (Tsuchida et al., 1997; Hu and Strittmatter, 2008). As the
antibody specifically recognizes human integrins, we performed
our experiments using motoneurons differentiated from hESCs,
following an established protocol (Patani et al., 2009). The results
we obtained were the same as those from DRG neurons. Activa-
tion of integrin, induced by TS2/16 antibody, alleviated the in-
hibitory effect of aggrecan on axon outgrowth, and enabled the
motoneurons to extend longer axons on aggrecan–laminin sub-
strates (low laminin, 72.5 m to 117.1 m, p  0.05; high
laminin, 138.1 m to 177.5 m, p  0.05, t test, n  3) (Fig.
4D,E). This indicates that earlier results obtained with manga-
nese treatment were attributable to its integrin-activating effect.
To confirm the generality of integrin modulation as a mech-
anism for inhibition of axon growth in the damaged CNS, we
performed a similar experiment as previously reported (Hu and
Strittmatter, 2008), demonstrating that Nogo-A inhibits axon
growth on laminin, but that this inhibition can be overcome by
activation of integrins with manganese (p  0.05, t test, n  3)
(Fig. 4F).
Discussion
The inhibitory effect of CSPGs on integrin signaling
There is evidence for various mechanisms mediating the inhibi-
tory action of aggrecan and other CSPGs on axon growth. Several
signaling pathways have been implicated, including Rho/ROCK
activation (Monnier et al., 2003), PKC activation (Sivasankaran
et al., 2004), and EGFR signaling (Koprivica et al., 2005). A recent
paper proposed that the transmembrane protein tyrosine phos-
phatase , PTP, is a receptor for CSPGs such as aggrecan and
neurocan, and mediates the growth-inhibitory effect of these
molecules (Shen et al., 2009). Our results suggest that these path-
ways may converge on the impairment of integrin function by
affecting their activation state, resulting in decreased integrin
signaling. An earlier study had showed that aggrecan inhibits
NGF-supported axon assembly on laminin without affecting
Figure4. Effect of integrin activation on axongrowthon inhibitory substrata.A,Manganese
treatment reverses the aggrecan-mediated inhibitory effect on integrin signaling. B–E, Addi-
tion of integrin activators, i.e., manganese to DRG neurons (B, C, scale bar, 50m) and TS2/16
4
to hESC-derived motoneurons (D, E, scale bar, 100m) reverses the inhibition of aggrecan on
axon growth. F, Manganese reverses Nogo-A-mediated inhibition on axon growth. All data are
mean SEM, and analyzed with Student’s t test. ***p 0.001; **p 0.01; *p 0.05; n.s.,
not significant.
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NGF-induced ERK phosphorylation, which led the authors to
infer that ECM-integrin signaling was a likely target for CSPGs
(Zhou et al., 2006). Here, we demonstrate that aggrecan, via its
glycan component, causes a suppression of integrin signaling,
starting with a decrease in pY397 FAK level, maximal at 2 min,
and decreasing thereafter. This is followed by decreases in further
downstream phosphorylation events via pY861 FAK and pY418
Src. Crucially, levels of surface 1 integrin were unaffected by
aggrecan treatment. These changes are in agreement with previ-
ous data with regards to the sequence of phosphorylation events
from integrin signaling (Parsons, 2003; Mitra and Schlaepfer,
2006). It is possible that interference with integrin signaling is a
general mechanism for inhibition of axon growth. Interestingly,
amino-Nogo also impairs integrin function and fibronectin-
induced pY397 FAK upregulation in cells (Hu and Strittmatter,
2008). Semaphorins, which are also expressed in the damaged
CNS, also impact integrin function (Pasterkamp and Giger,
2009).
Integrin activation promotes axon growth by enhancing
“outside-in” integrin signaling
Earlier studies have demonstrated that integrin activation in-
creases axon growth from PC-12 cells and mouse DRG neurons
(Ivins et al., 2000; Lein et al., 2000). We found that this effect is
dependent on substrate (laminin) concentration; i.e., integrin
activation only enhances axon growth at low laminin concentra-
tions but not on very low- or high-laminin substrata. A likely
explanation is that when presented with very low concentrations
of ligand, activation of integrins cannot override the paucity of
ligands, while at very high ligand concentrations, most integrins
are already activated and cannot be further activated. At low li-
gand concentrations, a high proportion of integrins are “inac-
tive,” allowing manganese to switch them into the “active” state
(Lemons and Condic, 2006).
The increase in ligand-binding affinity conferred by integrin
activation increases “outside-in” integrin signaling, as demon-
strated by enhanced phosphorylation of Y397 of FAK. Integrin
signaling enhancement in response to integrin activation was
rapid with pY397 FAK starting to rise within 2min of manganese
addition, reaching a plateau in 5 min at 150% of the control
level. That manganese induces a rapid integrin activation effect is
in agreementwith previouswork using flow cytometry and quan-
titative immunofluorescence to detect activated integrins (Baz-
zoni et al., 1998; Zhao et al., 2005; Lemons and Condic, 2006), as
well as functional assays (Nieswandt et al., 2007; Moser et al.,
2008).
Integrin activation allows axons to overcome inhibitory
influences
The inhibition of axon growth caused by CSPGs was successfully
overcome by activating integrins in neuronal cultures, using both
manganese and the integrin-activating antibody TS2/16 as the
activating agents. This could result either from integrin activation
overcoming a ligand-masking effect of CSPGs or through over-
coming CSPG-mediated integrin inactivation. Our data speak
against the first option: we grew axons in the presence of a large
excess of laminin (10 g/ml), yet aggrecan was still inhibitory at
these concentrations and treatment with integrin activators
(manganese or TS2/16) reversed this inhibition. We conclude
that integrin activation enhances axon growth on a CSPG-
containing substratum by reversing the inactivation caused by
the CSPG. Inhibition of axon growth through integrin inactiva-
tion may be a general mechanism, because Nogo-A exerts part of
its inhibitory effect in this way (Hu and Strittmatter, 2008).
Our results together with previous experiments demonstrate
that molecules that inhibit axon regeneration in the CNS act in
part by interfering with integrin function. Crucially, this inhibi-
tion can be overcome by enhancing the ligand-binding affinity of
integrin receptors on axons through integrin activation. Acti-
vation of axonal integrins should therefore promote axon re-
generation in the damaged CNS, where these inhibitors are
upregulated (Silver and Miller, 2004; Xie and Zheng, 2008). We
have shown that expression of an integrin that interacts with
tenascin-C, a glycoprotein upregulated in the damaged CNS, can
enhance axon regeneration after CNS damage (Andrews et al.,
2009). Transgenic expression of this integrin, coupledwith integ-
rin activation, should be a powerful method of promoting axon
regeneration in the damaged CNS.
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